Twi Biotechnology (6610.TWO) Stock Price

Twi Biotechnology Price

CLOSED
13.50
​
Market closed

Over the last 8 years Twi Biotechnology grew revenue by 41.2% annually, reaching 66.40 M TWD. For Twi Biotechnology, the net margin of -23.0% is up versus -139.7% a few years ago.

Twi Biotechnology stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Twi Biotechnology business model & stock analysis

TWi Biotechnology, Inc. generates revenue through contract revenue from Castal Creek Pharmaceuticals (CCP) for the drug AC-203, which treats epidermolysis bullosa (EB). The company focuses on repositioning drugs for rare diseases linked to innate immunity, particularly targeting the U.S. market. Its product pipeline includes two drug candidates for type II diabetes, arthritis, and immunodermatology, developed via in-licensing and internal research. The firm remains in the research and development phase, with no other revenue streams currently active. The company's primary customer is Castal Creek Pharmaceuticals (CCP), which has signed a contract for AC-203 development. CCP is a pharmaceutical company, and the contract involves drug development for epidermolysis bullosa (EB), a rare skin condition. TWi Biotechnology's strategy centers on building its pipeline through partnerships and internal R&D to address unmet medical needs in rare diseases. TWi Biotechnology, Inc. targets the U.S. market for its future products, focusing on rare disease treatments where innate immunity plays a key role. The company's current revenue source is limited to the CCP contract, while its product pipeline development continues to advance. The firm is not yet generating sales from its drug candidates, as it remains in the R&D stage.

Frequently asked questions about Twi Biotechnology

Converted at the current exchange rate, the Twi Biotechnology share trades at 0.37 EUR (13.50 TWD).

The revenue cannot currently be calculated for Twi Biotechnology.

The profit cannot currently be calculated for Twi Biotechnology.

The P/E ratio cannot be calculated for Twi Biotechnology at the moment.

The P/S cannot be calculated for Twi Biotechnology currently.

The Eulerpool Quality Score for Twi Biotechnology is 3/10.

The ISIN of Twi Biotechnology is TW0006610009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Twi Biotechnology is 6610.TWO. The ticker symbol is used to trade Twi Biotechnology shares on the stock exchange.

Fair ValueTerminal
14.31 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Dec 27, 2016
ISIN
TW0006610009
Cusip
Y9003E100
Market capitalization
2.75 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
4.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.71 %
Last updated Nov 22, 2026, 3:44 AM

Twi Biotechnology Peer Group

Twi Biotechnology FIGI

6610:TT (Taipei Stock Exchange) · BBG00FLZ6CS2